HOME PRODUCTS SERVICES COMPANY CONTACT FAQ

Metoclopramide (Reglan)

Subscribe to New Research on Metoclopramide

A dopamine D2 antagonist that is used as an antiemetic.

Also Known As:

Reglan; Maxolon; 4 Amino-5-chloro-N-(2-(diethylamino)ethyl)-2-methoxybenzamide; Cerucal; Metaclopramide; Metaclopromide; Metoclopramide Dihydrochloride; Metoclopramide Hydrochloride; Metoclopramide Monohydrochloride; Metoclopramide Monohydrochloride, Monohydrate; Primperan; Rimetin; Dihydrochloride, Metoclopramide; Hydrochloride, Metoclopramide; Monohydrochloride, Metoclopramide; Benzamide, 4-amino-5-chloro-N-(2-(diethylamino)ethyl)-2-methoxy-

Networked: 1940 relevant articles (302 outcomes, 361 trials/studies) for this Drug, Comments

Relationship Network

Drug Context: Research Results

Experts

1.	Fujii, Yoshitaka: 15 articles (11/2008 - 05/2002)
2.	Fujii, Y: 6 articles (10/2004 - 01/2000)
3.	Tanaka, H: 5 articles (03/2001 - 01/2000)
4.	Lipton, R B: 4 articles (11/2007 - 09/2000)
5.	Gallagher, E John: 3 articles (03/2009 - 10/2008)
6.	Bijur, Polly: 3 articles (03/2009 - 10/2008)
7.	Rudd, John A: 3 articles (12/2008 - 12/2003)
8.	Kan, Kelvin K W: 3 articles (12/2008 - 12/2003)
9.	Jankovic, Joseph: 3 articles (03/2008 - 01/2005)
10.	Nguyen, Nam Q: 3 articles (01/2008 - 02/2007)

Related Diseases

1.	Vomiting 11/01/1989 - "There was a significant reduction in the number of episodes of vomiting during the first 24 h in patients receiving the metoclopramide combination (P = 0.0001). " 11/01/1984 - "Pharmacokinetics and efficacy of high-dose metoclopramide given by continuous infusion for the control of cytotoxic drug-induced vomiting." 01/01/1985 - "The antiemetic potency of metoclopramide increased in a log linear manner, giving from 40% to 95% protection against emesis. " 12/01/1995 - "At this time, the reference treatment for emesis was metoclopramide and thus, phase III trials have been initially conducted with this comparative treatment. " 03/01/1986 - "[Randomized controlled study of high-dose metoclopramide (2 mg/kg x 4:H) vs moderate-dose metoclopramide (1 mg/kg x 4:M) in the prevention of CDDP-induced emesis]" Order ALL the reference details at left...
2.	Nausea 06/01/2000 - "There was a trend for improvement in the intensity of all symptoms on controlled-release metoclopramide with the exception of appetite, but this trend only reached statistical significance for nausea. " 12/01/1968 - "Metoclopramide in the treatment of nausea: a double blind trial." 03/01/2009 - "Patients who presented to our emergency department with a primary or secondary chief complaint of nausea were randomized to one of the following 4 groups: (1) metoclopramide 10 mg+diphenhydramine 25 mg; (2) metoclopramide 10 mg+placebo; (3) metoclopramide 20 mg+diphenhydramine 25 mg; (4) metoclopramide 20 mg+placebo. " 10/01/2004 - "Fifty-one patients who had nausea (> or = 3/10 on a 0-10 scale) for > or = 2 weeks despite 48 hours of oral metoclopramide therapy (40-60 mg/day) were enrolled. " 02/01/2003 - "CONCLUSION: Metoclopramide pretreatment attenuates the nausea and cramping associated with Yuzpe emergency contraceptive treatment." Order ALL the reference details at left...
3.	Postoperative Nausea and Vomiting (PONV) 08/01/2000 - "Metoclopramide, especially, has been studied extensively in the past, but there are no studies on the combination of both drugs for prevention of postoperative nausea and vomiting (PONV). " 11/01/1999 - "Metoclopramide in the prevention of postoperative nausea and vomiting: a quantitative systematic review of randomized, placebo-controlled studies." 08/01/1999 - "Metoclopramide, especially, has been studied extensively in the past, but there are no studies that used the combination of both drugs for prevention of postoperative nausea and vomiting (PONV). " 08/01/1999 - "A non-significant trend to reducing postoperative nausea and vomiting has been seen in two trials of intranasal metoclopramide. " 11/01/1996 - "The results from 109 patients enrolled in the study showed that this intranasal dose of metoclopramide may be ineffective in preventing the occurrence of PONV. " Order ALL the reference details at left...
4.	Migraine Disorders (Migraine) 01/01/2008 - "PERSPECTIVE: Metoclopramide appears to be an effective initial medical treatment for migraine headaches in the emergency department setting, but its pharmacologic mechanism remains incompletely understood. " 12/11/2004 - "CONCLUSIONS: Metoclopramide is an effective treatment for migraine headache and may be effective when combined with other treatments. " 10/01/1990 - "CONCLUSION: IV metoclopramide as a single agent is effective and safe therapy for migraine in the ED." 02/01/1993 - "The efficacy of metoclopramide in the treatment of migraine headache." 03/01/2008 - "To determine the role of combination therapy that includes oral metoclopramide in mild-to-moderate migraines, further studies are warranted." Order ALL the reference details at left...
5.	Neoplasms (Cancer) 01/01/1992 - "In the present tumor study, the dose scheduling of metoclopramide in combination with radiation was evaluated, and metoclopramide was shown to be most effective in potentiating the cytotoxic effect of radiation when administered one hour before radiation. " 05/01/1997 - "MATERIALS AND METHODS: Patient gender and age, clinical symptoms and signs, tumor localization, detection methods, findings on imaging studies, urinary catecholamine concentrations, results of metoclopramide stimulation tests, treatments at operation and tumor size were evaluated. " 04/01/2002 - "Anderson Cancer Center between 1994 and 1996, who were treated with a clinical care pathway that included NGT removal on postoperative day 1 and immediate use of promotility agents such as metoclopramide. " 01/01/2002 - "Forty-eight patients (25 female and 23 male; mean age 63 +/- 11 years) with a minimum two-week history of cancer-associated gastrointestinal symptoms were assigned to a single, open-label treatment group and received controlled-release metoclopramide 20 mg-80 mg q12h for a maximum period of 12 weeks (mean 46 +/- 35 days). " 06/01/2000 - "These results indicate that controlled-release metoclopramide reduces gastrointestinal symptoms in this population of advanced cancer patients." Order ALL the reference details at left...

Related Drugs and Biologics

1.	Ondansetron (Zofran)
2.	Dexamethasone (Maxidex)
3.	Cisplatin (Platino)
4.	Droperidol
5.	Granisetron (Kytril)
6.	Domperidone (Domperidon)
7.	Propofol (Diprivan)
8.	Antiemetics
9.	Methylprednisolone
10.	Diphenhydramine (Benadryl)

Related Therapies and Procedures

1.	Drug Therapy (Chemotherapy)
2.	Laparoscopic Cholecystectomy
3.	Tonsillectomy
4.	Gynecologic Surgical Procedures (Gynecologic Surgery)
5.	Thyroidectomy

blog comments powered by Disqus

TREATMENT OPTIONS
for Vomiting,
Ranking and Evidence

CureHunter Patient-Physician Summary Reports collect in one document all the medications ever reported in the US National Library of Medicine—1949 to the present—to be effective against your target disease. Analytic charts allow you and your physicians to see at a glance the treatment options—including new, promising, off-label and experimental.

Free Updates for 1 Year
All 1282 Outcomes
Top 200 Key Drugs and Biologics
Top 50 Key Therapies and Procedures
Detailed History Charts
Full Research Evidence References
Sample PDF Report on Psoriasis >>

Price:

$8.50 USD & Delivery via PDF download
updates for 1 year

Research Interface PRO

Rapidly retrieve clinical outcome summaries for all evidence of drug efficacy against any disease in seconds. Click "Charts" to view graphs of relative efficacy of all drugs against any known disease. CureHunter is unlike any "search engine" you have ever used. Where standard "search engines" produce lists of links, CureHunter quantifies evidence, extracts it from the literature and calculates a result you can use to immediately facilitate evidence based decision making in Real Clinical Time. Save hours of search and analysis time:

Two-clicks from Disease to Drug to Evidence: Drill down to full abstract
Enable Experts: Quickly identify key researchers and their publications
Enable FDA Link Generic: Two-clicks to FDA Products/Patents/Generics
Enable Export: All outcome statements and scores exportable to Excel/TSV for automated meta-analysis
Research Network: Explore drug and disease relationships visually
Enable Mobile Interface: Access from your cellphone, iPhone or PDA

Price:

$45.00 USD access via web interface
1 year subscription

Request Bulk Institution License Details >>